Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 330Breast Neoplasms 185Lung Neoplasms 177Ovarian Neoplasms 156Triple Negative Breast Neoplasms 88Fallopian Tube Neoplasms 75Squamous Cell Carcinoma of Head and Neck 74Small Cell Lung Carcinoma 67Esophageal Neoplasms 55Neoplasms 49Head and Neck Neoplasms 47Carcinoma, Ovarian Epithelial 44Uterine Cervical Neoplasms 36Esophageal Squamous Cell Carcinoma 36Endometrial Neoplasms 35Prostatic Neoplasms 33Neoplasm Metastasis 32Lymphoma, Large B-Cell, Diffuse 32Recurrence 31Adenocarcinoma of Lung 31Lymphoma 30Brain Neoplasms 29Neuroblastoma 24Central Nervous System Neoplasms 24Retinoblastoma 23Lymphoma, Non-Hodgkin 23Carcinoma, Squamous Cell 23Hodgkin Disease 20Testicular Neoplasms 19Urinary Bladder Neoplasms 16

Interventions

Pemetrexed 3pembrolizumab 1lenvatinib 1anlotinib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Non-squamous Non-small-cell Lung Cancer × Carboplatin × Clear all
NCT05258279 2024-08-28

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Juntendo University

Phase 2 Active not recruiting
30 enrolled
Thoracic

Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡